$0.959800
0.00020.02%
At close: Jul 2, 4:36 PM EDT
$0.960000
0.00020.02%
After Hours: 4:36 PM EDT
15 minutes delayed
Gossamer Bio
GOSSNASDAQ
Gossamer Bio (NASDAQ:GOSS) Stock, Analyst Ratings, Price Targets, Predictions
Gossamer Bio Inc has a consensus price target of $6.9, established from looking at the 44 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, Goldman Sachs, and HC Wainwright & Co. on June 25, 2024, June 17, 2024, and May 20, 2024. With an average price target of $9 between Oppenheimer, Goldman Sachs, and HC Wainwright & Co., there's an implied 837.50% upside for Gossamer Bio Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Goldman Sachs
HC Wainwright & Co.
Wedbush
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Gossamer Bio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/25/2024 | Buy Now | 837.5% | Oppenheimer | Andreas Argyrides | → $9 | Initiates | → Outperform | Get Alert |
| 06/17/2024 | Buy Now | 733.33% | Goldman Sachs | Paul Choi | $8 → $8 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 941.67% | HC Wainwright & Co. | Patrick Trucchio | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 316.67% | Wedbush | Laura Chico | → $4 | Reiterates | Outperform → Outperform | Get Alert |
| 05/06/2024 | Buy Now | 941.67% | HC Wainwright & Co. | Patrick Trucchio | → $10 | Reiterates | Buy → Buy | Get Alert |
| 04/05/2024 | Buy Now | 316.67% | Wedbush | Laura Chico | → $4 | Assumes | → Outperform | Get Alert |
| 03/27/2024 | Buy Now | 1462.5% | Piper Sandler | Yasmeen Rahimi | → $15 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 733.33% | Goldman Sachs | Paul Choi | $9 → $8 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 525% | Wedbush | Andreas Argyrides | → $6 | Reiterates | Outperform → Outperform | Get Alert |
| 03/06/2024 | Buy Now | 941.67% | HC Wainwright & Co. | Patrick Trucchio | → $10 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2024 | Buy Now | 941.67% | HC Wainwright & Co. | Patrick Trucchio | $5 → $10 | Maintains | Buy | Get Alert |
| 12/19/2023 | Buy Now | 525% | Wedbush | Andreas Argyrides | → $6 | Reiterates | Outperform → Outperform | Get Alert |
| 11/10/2023 | Buy Now | 525% | Wedbush | Andreas Argyrides | $5 → $6 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | 420.83% | Wedbush | Andreas Argyrides | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 08/10/2023 | Buy Now | 420.83% | HC Wainwright & Co. | Patrick Trucchio | → $5 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2023 | Buy Now | 420.83% | Wedbush | Andreas Argyrides | $7 → $5 | Maintains | Outperform | Get Alert |
| 07/26/2023 | Buy Now | 420.83% | HC Wainwright & Co. | Patrick Trucchio | → $5 | Reiterates | Buy → Buy | Get Alert |
| 07/21/2023 | Buy Now | 629.17% | Wedbush | Andreas Argyrides | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 05/11/2023 | Buy Now | 420.83% | HC Wainwright & Co. | Patrick Trucchio | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2023 | Buy Now | 56.25% | Barclays | Carter Gould | $2 → $1.5 | Maintains | Equal-Weight | Get Alert |
| 03/07/2023 | Buy Now | 420.83% | Raymond James | — | → $5 | Downgrade | Outperform → Market Perform | Get Alert |
| 03/01/2023 | Buy Now | — | Guggenheim | Vamil Divan | — | Initiates | → Neutral | Get Alert |
| 12/08/2022 | Buy Now | 420.83% | HC Wainwright & Co. | Patrick Trucchio | $25 → $5 | Maintains | Buy | Get Alert |
| 12/07/2022 | Buy Now | 941.67% | Goldman Sachs | Paul Choi | $22 → $10 | Maintains | Buy | Get Alert |
| 12/07/2022 | Buy Now | 733.33% | UBS | Eliana Merle | $19 → $8 | Maintains | Buy | Get Alert |
| 12/07/2022 | Buy Now | — | JP Morgan | Brian Cheng | — | Downgrade | Neutral → Underweight | Get Alert |
| 12/07/2022 | Buy Now | 108.33% | Barclays | Carter Gould | $18 → $2 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/07/2022 | Buy Now | 212.5% | SMBC Nikko | David Hoang | → $3 | Downgrade | Outperform → Neutral | Get Alert |
| 12/07/2022 | Buy Now | 420.83% | Raymond James | Steven Seedhouse | $15 → $5 | Maintains | Outperform | Get Alert |
| 12/07/2022 | Buy Now | 941.67% | SVB Leerink | Joseph Schwartz | $15 → $10 | Maintains | Outperform | Get Alert |
| 11/17/2022 | Buy Now | 1462.5% | Raymond James | Steven Seedhouse | $18 → $15 | Maintains | Outperform | Get Alert |
| 10/20/2022 | Buy Now | 2191.67% | Goldman Sachs | Paul Choi | → $22 | Initiates | → Buy | Get Alert |
| 09/21/2022 | Buy Now | 1670.83% | JP Morgan | Brian Cheng | → $17 | Initiates | → Neutral | Get Alert |
| 09/19/2022 | Buy Now | 2400% | Wedbush | Andreas Argyrides | → $24 | Initiates | → Outperform | Get Alert |
| 08/18/2022 | Buy Now | 1775% | Barclays | Carter Gould | $12 → $18 | Maintains | Overweight | Get Alert |
| 08/10/2022 | Buy Now | 1775% | Raymond James | Steven Seedhouse | $14 → $18 | Maintains | Outperform | Get Alert |
| 07/14/2022 | Buy Now | 1358.33% | Raymond James | Steven Seedhouse | $10 → $14 | Maintains | Outperform | Get Alert |
| 05/11/2022 | Buy Now | 1462.5% | SVB Leerink | Joseph Schwartz | $16 → $15 | Maintains | Outperform | Get Alert |
| 04/26/2022 | Buy Now | 1150% | Barclays | Carter Gould | $18 → $12 | Maintains | Overweight | Get Alert |
| 04/26/2022 | Buy Now | 941.67% | Raymond James | Steven Seedhouse | $19 → $10 | Maintains | Outperform | Get Alert |
| 04/18/2022 | Buy Now | 1879.17% | Raymond James | Timur Ivannikov | → $19 | Initiates | → Outperform | Get Alert |
| 04/06/2022 | Buy Now | 1879.17% | UBS | Eliana Merle | → $19 | Initiates | → Buy | Get Alert |
| 11/09/2021 | Buy Now | 1566.67% | SVB Leerink | Joseph Schwartz | — | Maintains | Outperform | Get Alert |
| 08/10/2021 | Buy Now | 1462.5% | SVB Leerink | Joseph Schwartz | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Gossamer Bio (GOSS) stock?
The latest price target for Gossamer Bio (NASDAQ:GOSS) was reported by Oppenheimer on June 25, 2024. The analyst firm set a price target for $9.00 expecting GOSS to rise to within 12 months (a possible 837.50% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Gossamer Bio (GOSS)?
The latest analyst rating for Gossamer Bio (NASDAQ:GOSS) was provided by Oppenheimer, and Gossamer Bio initiated their outperform rating.
When was the last upgrade for Gossamer Bio (GOSS)?
There is no last upgrade for Gossamer Bio
When was the last downgrade for Gossamer Bio (GOSS)?
The last downgrade for Gossamer Bio Inc happened on March 7, 2023 when Raymond James changed their price target from N/A to $5 for Gossamer Bio Inc.
When is the next analyst rating going to be posted or updated for Gossamer Bio (GOSS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gossamer Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gossamer Bio was filed on June 25, 2024 so you should expect the next rating to be made available sometime around June 25, 2025.
Is the Analyst Rating Gossamer Bio (GOSS) correct?
While ratings are subjective and will change, the latest Gossamer Bio (GOSS) rating was a initiated with a price target of $0.00 to $9.00. The current price Gossamer Bio (GOSS) is trading at is $0.96, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.